Stool Findings in Inflammatory Bowel Disease

Clinical Stool Characteristics

The American Gastroenterological Association recommends that increased stool frequency is the hallmark finding, with diarrhea being one of the primary presenting symptoms in both Crohn's disease and ulcerative colitis 3, 4, 5
Rectal bleeding occurs commonly, particularly in ulcerative colitis where mucosal inflammation starts distally in the rectum 3, 6, 5
Stool consistency varies from loose to watery depending on disease severity and location 6, 5

The American College of Gastroenterology notes that even after achieving endoscopic remission, only 29% and 41% of UC patients reported normal stool frequency at 8 and 52 weeks respectively, highlighting the disconnect between mucosal healing and functional symptoms 7, 1
Up to 27% of UC patients with both endoscopic and histologic healing continue to have increased stool frequency 7, 8, 9

The European Crohn’s and Colitis Organisation recommends that levels <50 μg/g of fecal calprotectin effectively rule out active IBD and suggest functional etiology 1, 9
Levels 50-250 μg/g represent a challenging gray zone requiring clinical correlation and possible serial monitoring 1
Levels >100-250 μg/g predict endoscopic activity and warrant ileocolonoscopy with biopsies 1, 2
Fecal calprotectin >100 μg/g supports IBD diagnosis with 93% sensitivity and 96% specificity 2
Thresholds of 200-250 μg/g may predict endoscopic remission in both UC and Crohn's disease 1

The American Gastroenterological Association recommends obtaining stool cultures and C. difficile toxin first to exclude infection 10, 5, 2
Measure fecal calprotectin once infection is excluded 1, 9
Document stool frequency, consistency, presence of blood, urgency, and nocturnal symptoms 1, 6, 5

Do not rely solely on stool frequency to assess disease activity, as 39% of IBD patients have overlapping functional symptoms that persist despite mucosal healing 7, 8, 9
Do not interpret mildly elevated calprotectin (50-250 μg/g) as definitively indicating active IBD 1
Do not skip infectious stool studies even in known IBD patients, as superimposed infection is common and alters management 10, 5, 2
Do not assume normal stool frequency equals remission, as up to 27% of patients with complete endoscopic and histologic healing continue having increased stool frequency 7, 1, 9

Serial fecal calprotectin monitoring at 3-6 month intervals facilitates early recognition of impending disease flares in patients with mild symptoms or those in apparent remission 1, 9